1. Tin-oxo clusters based on aryl arsonate anions
Yun-Peng Xie, Jin Yang, Jian-Fang Ma, Lai-Ping Zhang, Shu-Yan Song, Zhong-Min Su Chemistry. 2008;14(13):4093-103. doi: 10.1002/chem.200701498.
Reactions of Ph(3)SnOH or Ph3SnCl with aryl arsonic acids RAsO3H2, where R=C6H5 (1), 2-NH2C6H4 (2), 4-NH2C6H4 (3), 2-NO2C6H4 (4), 3-NO2C6H4 (5), 4-NO2C6H4 (6), 3-NO2-4-OHC6H3 (7), 2-ClC6H4 (8) and 2,4-Cl2C6H3 (9), gave 18 Sn-O cluster compounds. These compounds can be classified into four types: type A: [{(PhSn)3(RAsO3)3(mu3-O)(OH)(R'O)2}2Sn] (R=C6H5, 2-NH2C6H4, 4-NH2C6H4, 2-NO2C6H4, 3-NO2C6H4, 2-ClC6H4, 2,4-Cl2C6H3, and 3-NO2-4-OHC6H3; R'=Me or Et); type B: [{(PhSn)3(RAsO3)(2)(RAsO3H)(mu3-O)(R'O)2}2] (R=4-NO2C6H4, R'=Me); type C: [{(PhSn)3(RAsO3)3(mu3-O)(R'O)3}2Sn] (R=2,4-Cl2C6H3, R'=Me); type D: [{Sn3Cl3(mu3-O)(R'O)3}(2)(RAsO3)4] (R=2-NO2C6H4 and 4-NO2-C6H4; R'=Me or Et). Structures of types A and B contain [Sn3(mu3-O)(mu2-OR')2] building blocks, while in types C and D the stannoxane cores are built from two [Sn3(mu3-O)(mu2-OR')3] building blocks. The reactions proceeded with partial or complete dearylation of the triphenyltin precursor. These various structural forms are realized by subtle changes in the nature of the organotin precursors and aryl arsonic acids. The syntheses, structures, and structural interrelationship of these organostannoxanes are discussed.
2. Plant peptide hormone phytosulfokine (PSK-alpha): synthesis of new analogues and their biological evaluation
Agata Bahyrycz, Yoshikatsu Matsubayashi, Mari Ogawa, Youji Sakagami, Danuta Konopińska J Pept Sci. 2004 Jul;10(7):462-9. doi: 10.1002/psc.492.
Phytosulfokine-alpha (PSK-alpha), a sulfated growth factor (H-Tyr(SO3H)-Ile-Tyr(SO3H)-Thr-Gln-OH) universally found in both monocotyledons and dicotyledons, strongly promotes proliferation of plant cells in culture. In our studies on structure/activity relationship in PSK-alpha the synthesis of a series of analogues was performed: [H-D-Tyr(SO3H)1]- (9), [H-Phe(4-SO3H)1]- (10), [H-D-Phe(4-SO3H)1]- (11), [H-Phg(4-SO3H)1]- (12), [H-D-Phg(4-SO3H)1]- (13), H-Phe(4-NHSO2CH3)1]- (14), [H-D-Phe(4-NHSO2CH3)1]- (15), [H-Phe(4-NO2)1]- (16), [H-D-Phe(4-NO2)1]- (17), [H-Phg(4-NO2)1]- (18), [H-D-Phg(4-NO2)1]- (19), [H-Hph(4-NO2)1]- (20), [H-Phg(4-OSO3H)1]- (21), [Phe(4-NO2)3]- (22), [Phg(4-NO2)3]- (23), [Hph(4-NO2)3]- (24), [H-Phe(4-SO3H)1, Phe(4-SO3H)3]- (25) [H-Phe(4-NO2)1, Phe(4-NO2)3]- (26), [H-Phg(4-NO2)1, Phg(4-NO2)3]- (27), [H-Hph(4-NO2)1, Hph(4-NO2)3]- (28) and [Val3]- PSK-alpha (29). For modification of the PSK-alpha peptide chain the novel amino acids and their derivatives were synthesized, such as: H-L-Phg(4-SO3H)-OH (1), H-D-Phg(4-SO3H)-OH (2), Fmoc-Phg(4-SO3H)-OH (3), Fmoc-D-Phg(4-SO3H)-OH (4), Boc-Phg(4-NHSO2CH3)-OH (5), Boc-D-Phg(4-NHSO2CH3)-OH (6) Boc-Phe(4-NHSO2CH3)-OH (7), and Boc-D-Phe(4-NHSO2CH3)-OH (8). Peptides were synthesized by a solid phase method according to the Fmoc procedure on a Wang-resin. Free peptides were released from the resin by 95% TFA in the presence of EDT. All peptides were tested by competitive binding assay to the carrot membrane using 3H-labelled PSK according to the Matsubayashi et al. test.
3. Stimulation of insulin secretion from pancreatic islets by the cholecystokinin-tetrapeptide analogs Trp-Pro-Asp-Phe-NH2 and Trp-Pro-Asp-Phe(4'-NO2)-NH2
J J Knittel, B Hafner, D G Patel, E J Verspohl Pept Res. 1990 Sep-Oct;3(5):224-7.
The cholecystokinin-tetrapeptide (CCK4) analogs Trp-Pro-Asp-Phe-NH2 (3) and Trp-Pro-Asp-Phe-(4'-NO2)-NH2 (4) were found to be nearly equipotent to cholecystokinin-octapeptide (CCK8) in potentiating glucose-induced insulin secretion from islets of Langerhans isolated from rat pancreas. This stimulatory action was found to be dose-dependent and, in the case of 4, to exhibit a biphasic dose-response curve; i.e., at concentrations greater than 1.0 nM, the stimulating effect of 4 is reversed. These results suggest that conformational restriction of CCK4 and/or modification of the phenylalanine residue could produce more potent analogs capable of stimulating insulin release. Such compounds could have potential therapeutic utility in the treatment of non-insulin-dependent diabetes mellitus (NIDDM).
